Potential role of the cellular allergen stimulation test (CAST) in diagnosis of allergic bronchopulmonary aspergillosis (ABPA) in cystic fibrosis

2007 ◽  
Vol 42 (4) ◽  
pp. 314-318 ◽  
Author(s):  
Stephanie Ringer ◽  
Uta-Christina Hipler ◽  
Peter Elsner ◽  
Felix Zintl ◽  
Jochen Mainz
Keyword(s):  
Cystic Fibrosis ◽  
Potential Role ◽  
Allergic Bronchopulmonary Aspergillosis ◽  
Stimulation Test

scholarly journals The Use of Targeted Monoclonal Antibodies in the Treatment of ABPA—A Case Series

Medicina ◽  
2021 ◽  
Vol 58 (1) ◽  
pp. 53
Author(s):  
Aoife O’Reilly ◽  
Eleanor Dunican
Keyword(s):  
Cystic Fibrosis ◽  
Potential Role ◽  
Antifungal Agents ◽  
Case Reports ◽  
Allergic Bronchopulmonary Aspergillosis ◽  
Case Series ◽  
Pulmonary Disorder ◽  
The Impact

Allergic bronchopulmonary aspergillosis (ABPA) is a pulmonary disorder occurring in response to Aspergillus fumigatus that can complicate the course of asthma and cystic fibrosis. Here we present a case of acute ABPA without central bronchiectasis, a case of chronic active ABPA with central bronchiectasis, and a case of severe relapsing ABPA with central bronchiectasis. All three were initially treated with corticosteroids and antifungal agents but had an incomplete response. These patients were then treated with anti-IgE therapy with omalizumab before being switched to the anti-IL5R agent benralizumab. They responded well to both agents. These case reports highlight the potential role of omalizumab and benralizumab in the treatment of ABPA, but further studies are required to evaluate the effectiveness of these medications. Longer follow-up periods and objective measurements of the impact of treatment are necessary.

Role of omalizumab in the management of allergic bronchopulmonary aspergillosis in patients with cystic fibrosis

2015 ◽  
Vol 144 (4) ◽  
pp. 190-191
Author(s):  
Isabel Delgado Pecellín ◽  
Esther Quintana Gallego ◽  
Celeste Pedregal Solano ◽  
Carmen Calero Acuña
Keyword(s):  
Cystic Fibrosis ◽  
Allergic Bronchopulmonary Aspergillosis

scholarly journals Posaconazole therapy in children with cystic fibrosis and Aspergillus-related lung disease

2019 ◽  
Vol 58 (1) ◽  
pp. 11-21 ◽  
Author(s):  
Deepa Patel ◽  
Sarah Popple ◽  
Alison Claydon ◽  
Deborah E Modha ◽  
Erol A Gaillard
Keyword(s):  
Cystic Fibrosis ◽  
Lung Disease ◽  
Plasma Levels ◽  
Allergic Bronchopulmonary Aspergillosis ◽  
Tablet Formulation ◽  
Full Blood Count ◽  
Systemic Corticosteroids ◽  
Liquid Preparation ◽  
A Prospective Study

Abstract There is emerging evidence for the role of posaconazole in the management of Aspergillus-related cystic fibrosis (CF) lung disease. The tolerability and efficacy of posaconazole in paediatric CF is not well established. We report a prospective study over a fifty-three month period evaluating the safety, tolerability, and efficacy of posaconazole in pediatric CF. Fourteen children (seven males, median age 13 years, range 3–17 years) received a total of twenty-three courses of posaconazole (13 oral suspension and 10 tablet formulation). Of these patient episodes, nine received posaconazole for emerging or active allergic bronchopulmonary aspergillosis (ABPA) and two required a combination of posaconazole and systemic corticosteroids for difficult-to-treat ABPA. A subgroup of patients (n = 12) with persistent isolates of Aspergillus fumigatus, in the absence of serological markers of ABPA, received posaconazole monotherapy for pulmonary exacerbations not responding to conventional broad-spectrum antibiotic treatment. Posaconazole levels, full blood count, electrolytes, and liver function were monitored on day 7 of treatment and then monthly. Posaconazole was well tolerated in all but three patients. Therapeutic plasma levels >1 mg/l were achieved in all receiving the tablet formulation in comparison to 60% on the liquid preparation. There was a modest but significant improvement in FEV1 (% predicted) demonstrated for the cohort as a whole (p = 0.015) following posaconazole therapy. Posaconazole is well tolerated in children as young as six years old, improvements in lung function are observed, and therapeutic plasma levels are readily achieved in patients taking the tablet formulation and in adherent patients taking the liquid formulation.

scholarly journals Case Report: Dual nebulised antibiotics among adults with cystic fibrosis and chronic Pseudomonas infection

F1000Research ◽  
2017 ◽  
Vol 6 ◽  
pp. 2079
Author(s):  
Nina Mann ◽  
Shirley Murray ◽  
Zhe Hui Hoo ◽  
Rachael Curley ◽  
Martin J. Wildman
Keyword(s):  
Cystic Fibrosis ◽  
Case Report ◽  
Adverse Effects ◽  
Best Practice ◽  
Potential Role ◽  
Concomitant Administration ◽  
Intravenous Antibiotics ◽  
Inhaled Antibiotics ◽  
Pseudomonas Infection

Pulmonary exacerbations in adults with cystic fibrosis (CF) and chronic Pseudomonas aeruginosa (Psae) infection are usually treated with dual intravenous antibiotics for 14 days, despite the lack of evidence for best practice. Intravenous antibiotics are commonly associated with various systemic adverse effects, including renal failure and ototoxicity. Inhaled antibiotics are less likely to cause systematic adverse effects, yet can achieve airway concentrations well above conventional minimum inhibitory concentrations. Typically one inhaled antibiotic is used at a time, but dual inhaled antibiotics (i.e. concomitant use of two different inhaled antibiotics) may have synergistic effect and achieve better results in the treatment of exacerbations. We presented anecdotal evidence for the use of dual inhaled antibiotics as an acute treatment for exacerbations, in the form of a case report. A female in her early thirties with CF and chronic Psae infection improved her FEV1 by 5% and 2% with two courses of dual inhaled antibiotics to treat exacerbations in 2016. In contrast, her FEV1 changed by 2%, –2%, 0% and 2%, respectively, with four courses of dual intravenous antibiotics in 2016. Baseline FEV1 was similar prior to all six courses of treatments. The greater FEV1 improvements with dual inhaled antibiotics compared to dual intravenous antibiotics suggest the potential role of using dual inhaled antibiotics to treat exacerbations among adults with CF and chronic Psae infection, especially since a greater choice of inhaled anti-pseudomonal antibiotics is now available. A previous study in 1985 has looked at the concomitant administration of inhaled tobramycin and carbenicillin, by reconstituting antibiotics designed for parenteral administration. To our knowledge, this is the first literature to describe the concomitant use of two different antibiotics specifically developed for delivery via the inhaled route.

scholarly journals Cystic fibrosis as a bowel cancer syndrome and the potential role of CK2

2008 ◽  
Vol 316 (1-2) ◽  
pp. 169-175 ◽  
Author(s):  
Anil Mehta
Keyword(s):  
Cystic Fibrosis ◽  
Potential Role ◽  
Bowel Cancer ◽  
Cancer Syndrome

scholarly journals Potential Role of High-Mobility Group Box 1 in Cystic Fibrosis Airway Disease

2008 ◽  
Vol 178 (8) ◽  
pp. 822-831 ◽  
Author(s):  
Steven M. Rowe ◽  
Patricia L. Jackson ◽  
Gang Liu ◽  
Mathew Hardison ◽  
Alessandra Livraghi ◽  
...  
Keyword(s):  
Cystic Fibrosis ◽  
Potential Role ◽  
High Mobility ◽  
Airway Disease ◽  
High Mobility Group ◽  
Cystic Fibrosis Airway

Role of chest radiography in the diagnosis of allergic bronchopulmonary aspergillosis in adult patients with cystic fibrosis

2007 ◽  
Vol 112 (5) ◽  
pp. 626-636 ◽  
Author(s):  
G. Cortese ◽  
V. Malfitana ◽  
R. Placido ◽  
A. Ferrari ◽  
B. Grosso ◽  
...  
Keyword(s):  
Cystic Fibrosis ◽  
Chest Radiography ◽  
Allergic Bronchopulmonary Aspergillosis ◽  
Adult Patients

scholarly journals Fungal Infection and Inflammation in Cystic Fibrosis

Pathogens ◽  
2021 ◽  
Vol 10 (5) ◽  
pp. 618
Author(s):  
T. Spencer Poore ◽  
Gina Hong ◽  
Edith T. Zemanick
Keyword(s):  
Cystic Fibrosis ◽  
Lung Disease ◽  
Clinical Outcomes ◽  
Fungal Infections ◽  
Allergic Bronchopulmonary Aspergillosis ◽  
Lower Airway ◽  
Future Research ◽  
Isolation And Identification ◽  
Helper Cell Type

Fungi are frequently recovered from lower airway samples from people with cystic fibrosis (CF), yet the role of fungi in the progression of lung disease is debated. Recent studies suggest worsening clinical outcomes associated with airway fungal detection, although most studies to date are retrospective or observational. The presence of fungi can elicit a T helper cell type 2 (Th-2) mediated inflammatory reaction known as allergic bronchopulmonary aspergillosis (ABPA), particularly in those with a genetic atopic predisposition. In this review, we discuss the epidemiology of fungal infections in people with CF, risk factors associated with development of fungal infections, and microbiologic approaches for isolation and identification of fungi. We review the spectrum of fungal disease presentations, clinical outcomes after isolation of fungi from airway samples, and the importance of considering airway co-infections. Finally, we discuss the association between fungi and airway inflammation highlighting gaps in knowledge and future research questions that may further elucidate the role of fungus in lung disease progression.

Potential role of macrolide antibiotics in the management of cystic fibrosis lung disease

2002 ◽  
Vol 8 (6) ◽  
pp. 521-528 ◽  
Author(s):  
Thao Nguyen ◽  
Stan G. Louie ◽  
Paul M. Beringer ◽  
Mark A. Gill
Keyword(s):  
Cystic Fibrosis ◽  
Lung Disease ◽  
Potential Role ◽  
Cystic Fibrosis Lung ◽  
Macrolide Antibiotics ◽  
Cystic Fibrosis Lung Disease
Sign in / Sign up

Export Citation Format

Share Document